GMAB vs PFE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: PFE is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GMAB and PFE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GMAB and PFE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Genmab A/S, founded in 1999 and headquartered in Copenhagen, engineers therapeutic antibodies and has historically licensed them to larger partners rather than selling them itself. The best known is daratumumab, sold by Johnson & Johnson as DARZALEX and DARZALEX FASPRO, which has become a backbone therapy in multiple myeloma and pays Genmab a royalty on worldwide net sales. Genmab also earns royalties on ofatumumab (Kesimpta, Novartis) and teprotumumab (TEPEZZA), and shares in two commercial products it helped develop: epcoritamab, sold as EPKINLY in the US and TEPKINLY in Europe with AbbVie, and tisotumab vedotin (TIVDAK) with Pfizer. The strategic shift under way is toward owning products outright. Rina-S (rinatabart sesutecan), a folate receptor alpha antibody-drug conjugate in ovarian cancer, is wholly owned, and the December 2025 close of the $8 billion all-cash acquisition of Merus N.V. at $97 per share added petosemtamab, a late-stage bispecific in head and neck cancer.

Full GMAB guide

Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. Its portfolio spans oncology (a strategic priority, expanded sharply by the acquisition of cancer drugmaker Seagen), vaccines (including pneumococcal franchise Prevnar and its COVID-19 vaccine Comirnaty, partnered with BioNTech), internal medicine and cardiology (such as the Vyndaqel/Vyndamax family and Eliquis, co-marketed with Bristol Myers Squibb), immunology and inflammation, and antivirals (including the COVID treatment Paxlovid). Pfizer makes money selling these drugs to wholesalers, pharmacies, hospitals, and governments worldwide. The company saw an enormous revenue surge from COVID-19 products during the pandemic, then a steep decline as that demand normalized, leaving it to refill growth through its pipeline, oncology expansion, and acquisitions while a wave of patent expirations looms later this decade. Founded in 1849 and headquartered in New York City, Pfizer is a mature, dividend-paying large-cap navigating a post-COVID reset.

Full PFE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GMAB drivers: DARZALEX royalties still compounding; EPKINLY as the first real commercial franchise.
• PFE drivers: Oncology expansion via Seagen; Broad, diversified portfolio.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Revenue concentration is the first-order risk: DARZALEX royalties were roughly 64% of first-half 2026 revenue, Genmab does not control how the drug is priced or promoted, and daratumumab exclusivity does not last forever, so the whole equity story is a race between pipeline conversion and eventual biosimilar erosion. For PFE, pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap.

Pick GMAB if you believe its drivers more; PFE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GMAB and PFE guides.

GMAB. Figures are approximate and tied to the asOf date; verify live numbers before acting. Genmab is unusual for a mid-cap biotech in being consistently profitable, because the royalty line carries almost no cost, so screening it on earnings multiples against pre-revenue biotech peers is not informative. The more useful framing is that a large share of current profit comes from an asset Genmab neither sells nor controls, so the multiple reflects a market judgment on the wholly owned pipeline rather than on the current royalty. Reported profit also now absorbs the operating costs and accounting effects of the Merus acquisition, which is why adjusted operating profit and reported operating profit have separated.

PFE. Pfizer trades at a below-market multiple and a high dividend yield, reflecting investor concern about the post-COVID revenue reset and a looming patent cliff. Its valuation balances substantial cash generation and diversification against questions over whether the pipeline and Seagen-led oncology push can restore durable growth.

Headline figures (approximate, August 2026): GMAB shows revenue (ttm) ~$4.1 billion, presented in US dollars (H1 2026 was ~$2.05 billion, up ~25% year over year), darzalex royalties (h1 2026) ~$1.31 billion, up ~20%, roughly 64% of total revenue, owned and shared product sales (h1 2026) EPKINLY and TEPKINLY ~$312 million (up ~48%), TIVDAK ~$84 million, profitability (h1 2026) Operating profit ~$555 million; adjusted operating profit ~$656 million; PFE shows revenue (ttm) ~$60 billion, operating margin ~25%, recovering post-COVID normalization, net income (ttm) multi-billion, variable with COVID product swings, dividend yield ~6%, high for large-cap pharma.

GMAB and PFE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GMAB and PFE exposure against your real portfolio. It is not an investment adviser.